Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Paten
Post# of 421
(Total Views: 177)
Posted On: 03/02/2023 4:57:43 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation
- Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
- DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
- Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
- Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.
Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.
In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.
HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.
“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://nnw.fm/zK6Jt ). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”
Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.
“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
- DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
- Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
- Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.
Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.
In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.
HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.
“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://nnw.fm/zK6Jt ). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”
Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.
“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)